echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > FDA Approves Innovative Topical Compound Combination for the Treatment of Skin Diseases That Troubled 85% of Teenagers

    FDA Approves Innovative Topical Compound Combination for the Treatment of Skin Diseases That Troubled 85% of Teenagers

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 27, 2021, Sol-Gel Technologies announced that the US FDA has approved its innovative combination therapy Twyneo cream for the treatment of acne vulgaris (acne vulgaris) in adults and children aged 9 years and older
    .
    Twyneo is a fixed-dose compound topical cream containing 0.
    1% tretinoin and 3% benzoyl peroxide.
    Clinical trials have proved that it has significant efficacy and good safety characteristics

    .
    The press release pointed out that this is also the first fixed-dose combination of these two drugs approved by the FDA

    .

    Acne vulgaris is a common multifactorial skin disease that most commonly occurs in children and adolescents, affecting 80%-85% of adolescents, but it may also occur in adults
    .
    Skin lesions appear in areas where a large number of oil glands in the patient’s body, such as the face, chest, neck, and back, are inflammatory (papules, pustules, nodules) or non-inflammatory (acne) lesions

    .
    Acne can have a profound impact on the quality of life of patients

    .
    In addition to the major risk of permanent facial scars, it may also cause psychological stress, social fear, and decreased self-esteem

    .

    Tretinoin and benzoyl peroxide are widely used in the treatment of acne vulgaris, respectively.
    If the effects of the two drugs can be used at the same time, the curative effect on patients will be stronger

    .
    However, because benzoyl peroxide can cause the degradation of tretinoin molecules, its combination therapy may reduce the efficacy of tretinoin

    .
    In order to solve this problem, Twyneo uses Sol-Gel's microencapsulation technology to encapsulate tretinoin and benzoyl peroxide in silica microcapsules.
    This structure can stabilize tretinoin and benzoyl peroxide.
    It is degraded by benzoyl peroxide and can slowly release the respective active pharmaceutical ingredients over time, resulting in good efficacy and safety characteristics

    .

    ▲Sol-Gel's microencapsulated drug delivery technology (picture source: Sol-Gel's official website)

    The approval is based on the positive results of two randomized, double-blind, excipient-controlled, multi-center Phase 3 clinical trials
    .
    Test data show that Twyneo has significant efficacy and well tolerated characteristics in patients with facial acne vulgaris 9 years and older

    .

    Note: The original text has been deleted

    Reference materials:

    [1] Sol-Gel Technologies Announces FDA Approval of TWYNEO.
    Retrieved July 28, 2021, from https://ir.
    sol-gel.
    com/news-releases/news-release-details/sol-gel-technologies-announces- fda-approval-twyneor

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.